Montelukast is NOT recommended for treating itching as a primary indication
Montelukast should not be used as a treatment for generalized pruritus (itching) without an underlying dermatosis, as it lacks evidence of efficacy for this indication. The most authoritative guideline on generalized pruritus explicitly states that sodium cromoglycate, montelukast, and antihistamines are not recommended for managing eosinophilic esophagitis-related symptoms, and may only have a role in concomitant atopic disease 1. Similarly, the British Association of Dermatologists' comprehensive 2018 guidelines for generalized pruritus management do not include montelukast among recommended treatments for any form of itching 2.
Evidence Against Montelukast for Itching
The FDA-approved indications for montelukast are limited to:
- Asthma prophylaxis and chronic treatment
- Prevention of exercise-induced bronchoconstriction
- Relief of seasonal and perennial allergic rhinitis symptoms 3
Pruritus (itching) is not an FDA-approved indication for montelukast.
Limited Exception: Atopic Dermatitis with Itching
The only context where montelukast shows any evidence for itch reduction is in atopic dermatitis specifically, not generalized pruritus:
- Small studies in children with moderately severe atopic dermatitis showed montelukast reduced itching scores, sleep disturbance, disease extent, and blood eosinophil counts 4, 5
- One study found montelukast significantly suppressed itching in skin prick tests (p=0.02) 6
- However, these were small, open-label trials with significant methodological limitations
Even for atopic dermatitis, the 2024 American Academy of Dermatology guidelines state there is insufficient data to recommend montelukast 7.
When Montelukast Might Be Considered
Montelukast may be appropriate only when:
- Itching is secondary to concomitant allergic disease (asthma or allergic rhinitis) where montelukast is already indicated 1, 8
- Patient has atopic dermatitis with documented allergic rhinitis or asthma requiring treatment for those conditions 8, 9
- Other evidence-based treatments for pruritus have been optimized (emollients, topical corticosteroids, antihistamines for urticaria, etc.) 2
Recommended Approach for Itching Instead
For generalized pruritus, evidence-based treatments include:
- First-line: Emollients, identify and treat underlying cause 2
- Uremic pruritus: BB-UVB phototherapy (Strength A), gabapentin 2
- Hepatic pruritus: Rifampicin first-line (Strength A), cholestyramine second-line 2
- Urticaria: Non-sedating H1-antihistamines (up to 4x standard dose), omalizumab for refractory cases 10
- Atopic dermatitis: Topical corticosteroids, calcineurin inhibitors, dupilumab, JAK inhibitors 7
Common Pitfall to Avoid
Do not prescribe montelukast simply because a patient complains of itching. The drug lacks efficacy data for pruritus as a primary symptom and carries neuropsychiatric risks (FDA black box warning) that must be weighed against any potential benefit 3, 11. Always identify the underlying cause of itching and use evidence-based treatments specific to that condition.